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ABSTRACT There is controversy concerning the role of dihydroceramide desaturase
(Degs1) in regulating cell survival, with studies showing that it can both promote and
protect against apoptosis. We have therefore investigated the molecular basis for these
opposing roles of Degs1. Treatment of HEK293T cells with the sphingosine kinase inhibi-
tor SKi [2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole] or fenretinide, but not the Degs1
inhibitor GT11 {N-[(1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl-
]octan-amide}, induced the polyubiquitination of Degs1 (Mr  40 to 140 kDa) via a
mechanism involving oxidative stress, p38 mitogen-activated protein kinase (MAPK), and
Mdm2 (E3 ligase). The polyubiquitinated forms of Degs1 exhibit “gain of function” and
activate prosurvival pathways, p38 MAPK, c-Jun N-terminal kinase (JNK), and X-box pro-
tein 1s (XBP-1s). In contrast, another sphingosine kinase inhibitor, ABC294640 [3-(4-
chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide], at concentra-
tions of 25 to 50 M failed to induce formation of the polyubiquitinated forms of
Degs1. In contrast to SKi, ABC294640 (25 M) promotes apoptosis of HEK293T cells via a
Degs1-dependent mechanism that is associated with increased de novo synthesis of cer-
amide. These ﬁndings are the ﬁrst to demonstrate that the polyubiquitination of Degs1
appears to change its function from proapoptotic to prosurvival. Thus, polyubiquitina-
tion of Degs1 might provide an explanation for the reported opposing functions of this
enzyme in cell survival/apoptosis.
KEYWORDS dihydroceramide desaturase, sphingosine 1-phosphate, ER stress,
proteasome, sphingosine kinase
D
e novo synthesis of ceramide involves a pathway in which serine and palmitoyl CoA
undergo condensation to form 3-ketosphinganine, which is catalyzed by serine
palmitoyltransferase and which is the rate-limiting step in ceramide biosynthesis (1).
3-Ketosphinganine is converted into sphinganine (dihydrosphingosine) by 3-ketosphinganine
reductase, which is then acylated to dihydroceramide by ceramide synthase (CerS).
Dihydroceramide desaturase (Degs1) introduces a trans 4,5 double bond to dihydro-
ceramide, thereby forming ceramide de novo. Ceramide can also be formed by the
sphingomyelinase-catalyzed hydrolysis of sphingomyelin in the so-called “salvage”
pathway. Deacylation of ceramide by ceramidase produces sphingosine (Sph), which is
then phosphorylated by sphingosine kinase 1 (SK1) or SK2 to form sphingosine
1-phosphate (S1P). Sphingosine kinase can also phosphorylate sphinganine to produce
sphinganine 1-phosphate (dihydrosphingosine 1-phosphate). S1P is either cleaved by
S1P lyase (to hexadecenal and phosphoethanolamine) or converted back to ceramide,
via sphingosine, by S1P phosphatase and CerS. In general terms, ceramide and sphin-
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gosine promote senescence or apoptotic cell death (1, 2), while S1P promotes cell
growth (3).
Although initially regarded as simply intermediates in de novo ceramide biosynthe-
sis, dihydroceramides are now recognized to have distinct biological functions, includ-
ing in relation to autophagy, cell proliferation, hypoxia, and several diseases (4). For
example, dihydroceramides that accumulate in response to Degs1 inhibitors or the
addition of exogenous dihydroceramides promotes autophagy (5–7) and endoplasmic
reticulum (ER) stress (7). However, some effects of Degs1 inhibitors on autophagy are
independent of dihydroceramides (8). Nonetheless, genetic evidence supports a role for
dihydroceramides in autophagy, which is linked with cell survival. Thus, Degs1 deﬁ-
ciency produces an antiapoptotic effect via activation of AKT and autophagy (9).
However, other studies have shown that inhibition of Degs1 promotes cell death, which
may involve autophagy or apoptosis (7, 10). For example, apoptosis is induced by
Degs1 inhibitors, including fenretinide and resveratrol (11–13), and this is prevented
when enzymes upstream of Degs1 in the de novo ceramide synthesis pathway are
inhibited (12). In contrast, inhibition of Degs1 or its genetic manipulation can produce
resistance to apoptosis (7, 9, 14, 15).
One mechanism by which Degs1 might regulate cell survival is via ER stress, as lipid
composition and particularly ceramide and dihydroceramide in the ER membrane
activate ER stress responses (7, 16, 17). This can lead to an unfolded protein response
(UPR), which is a survival process; however, a sustained UPR results in apoptosis (18). ER
stress involves the dissociation of the ER chaperone binding immunoglobulin protein
(BiP) from the lumenal domains of ER stress sensors, which are protein kinase R-like ER
kinase (PERK), inositol-requiring kinase 1 (IRE1), and activating transcription factor 6
(ATF6). PERK is a kinase which phosphorylates the  subunit of eukaryotic initiation
factor 2 (eIF2) to inhibit protein synthesis. ER stress also initiates ER-associated protein
degradation (ERAD) to remove misfolded proteins. Recent studies have demonstrated
that the SK2 inhibitor ABC294640 [3-(4-chlorophenyl)-adamantane-1-carboxylic acid
(pyridin-4-ylmethyl)amide] or K145 induces ER stress, with the latter increasing the
expression of X-box protein 1s (XBP-1s) and p-eIF2 (19). Targeting SK2 with K145 also
contributed to ER stress and UPR activation induced by bortezomib, as evidenced by
stimulation of the IRE1, c-Jun N-terminal kinase (JNK), and p38 mitogen-activated
protein kinase (MAPK) pathways, thereby resulting in potent synergistic apoptosis of
myeloma cells in vitro (19). We have also shown that 2-(p-hydroxyanilino)-4-(p-
chlorophenyl)thiazole (SKi) induces ER stress/UPR in T-cell lymphoblastic leukemic
(T-ALL) cells that results in protective cell survival autophagy (20). The effects of
ABC294640 and SKi on Degs1 activity therefore raise the possibility for their involve-
ment in both a “survival”-promoting UPR and an “apoptotic” UPR.
Given the current controversy surrounding the role of Degs1 in regulating cell
survival versus apoptosis, we have investigated the molecular basis for these opposing
roles of Degs1. We demonstrate that Degs1 is subject to regulation by polyubiquiti-
nation induced by the sphingosine kinase inhibitor SKi or fenretinide. Polyubiquitina-
tion of Degs1 promotes a “gain of function,” which enables the activation of prosurvival
pathways, including p38 MAPK, JNK, and XBP-1s. In contrast, another sphingosine
kinase inhibitor, ABC294640, failed to induce polyubiquitination of Degs1 at a concen-
tration that increases de novo synthesis of ceramide and induces apoptosis via a
Degs1-dependent mechanism. These ﬁndings are the ﬁrst to suggest that the opposing
functions of Degs1 in cell survival and apoptosis might be due to the polyubiquitina-
tion of Degs1.
RESULTS
Effects of ABC294640 and SKi on the polyubiquitination of Degs1. The sphin-
gosine kinase inhibitors SKi and ABC294640 have previously been shown to reduce
Degs1 activity, and this is associated with the proteasomal degradation of the enzyme
in androgen-independent LNCaP-AI prostate cancer cells (21). We therefore assessed
the effects of these SK inhibitors on Degs1 expression levels in HEK293T cells. Native
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Degs1 is expressed as a 32-kDa protein in HEK293T cells, detected with an anti-Degs1
antibody on Western blots (Fig. 1A). Treatment of HEK293T cells with SKi (10 M for 24
h) induced the appearance of a ladder of higher-molecular-mass protein bands that
immunoreacted with anti-Degs1 antibody (Fig. 1A), suggesting that SKi can stimulate
the posttranslational modiﬁcation of Degs1. Conﬁrmation of their identity was estab-
lished using small interfering RNA (siRNA) to knock down Degs1 expression, which
reduced the immunoreactive intensity of the 32-kDa protein and that of the laddered
protein bands (Fig. 1B), e.g., an 80% reduction in the expression of the 46-kDa
posttranslationally modiﬁed form of Degs1 (Fig. 1B). In contrast to SKi, treatment of
HEK293T cells with ABC294640 (25 M for 24 h) did not induce the formation of the
Degs1 ladder (Fig. 1A). Identical results were obtained with the parental HEK293 cell
line (data not shown).
We also sought a second independent method to conﬁrm the identity of the proteins
in the ladder. In this regard, the posttranslationally modiﬁed forms of Degs1 are present in
a high-speed pellet fraction containing cell membranes (Fig. 1C) and can be released into
a high-speed supernatant fraction using deoxycholate-containing buffer but not NP-40
(data not shown). By using this method, the posttranslationally modiﬁed forms of Degs1
were immunoprecipitated by the anti-Degs1 antibody (Fig. 1D).
Ubiquitination, which is catalyzed by E3 ligase, will typically promote posttransla-
tional modiﬁcation of proteins that can be resolved on SDS-PAGE gels as a ladder
similar to that observed here for Degs1. We therefore transfected HEK293T cells with a
plasmid construct encoding hemagglutinin (HA)-tagged ubiquitin and then treated
these cells with SKi (10 M for 24 h), after which Degs1 was immunoprecipitated with
anti-Degs1 antibody and then probed with anti-HA antibody on Western blots. SKi
promoted the formation of a ladder of HA-ubiquitinated Degs1 forms (Fig. 1E). The
HA-ubiquitinated Degs1 laddering in immunoprecipitates was similar to that detected
in immunoprecipitates probed with anti-Degs1 antibody on Western blots (Fig. 1D).
Unpublished research from our laboratory has demonstrated that SKi promotes the
ubiquitination of p53, which is catalyzed by Mdm2 (22). We therefore considered
whether Mdm2 might be involved in regulating the ubiquitination of Degs1. Indeed,
the formation of the Degs1 ladder in response to SKi was reduced when cells were
pretreated with a speciﬁc inhibitor of Mdm2, nutlin (Fig. 1F).
Effect of the proteasome inhibitor MG132 on the polyubiquitination of Degs1.
Given that the formation of the Degs1 ladder appears to reﬂect ongoing ubiquitin-
proteasomal degradation, we assessed whether the proteasome inhibitor MG132
(carbobenzoxy-Leu-Leu-leucinal) induces the formation of the Degs1 ladder, and, in-
deed, this was the case (Fig. 1A and 2A). Interestingly, there were additional anti-Degs1
immunoreactive protein bands with molecular masses below 32 kDa that are not
formed in response to SKi (Fig. 1A and 2A). These smaller Degs1 forms might represent
proteasomal degradation products that have accumulated due to inhibition of the
proteasome by MG132. The identity of the proteins formed in response to MG132 was
conﬁrmed using Degs1 siRNA (Fig. 2A). These ﬁndings suggest that Degs1 is subject to
dynamic turnover in HEK293T cells.
We therefore assessed whether combined treatment of cells with SKi and MG132
had any effect on the formation of the Degs1 ladder. In this regard, combined
treatment increased the formation of Degs1 forms with aMr of 50 kDa (Fig. 2A), which
represent polyubiquitinated forms of Degs1. Formation of the Degs1 ladder is a feature
of proteasome inhibition, as a second proteasome inhibitor, bortezomib, which is
chemically distinct from MG132, induced the same effect on Degs1 (Fig. 2B).
In order to establish whether Degs1 is subject to ubiquitin-proteasomal degradation
in cancer cells, we treated PANC1 cancer cells with SKi and MG132. PANC1 cells express
the native 32-kDa form of Degs1 (Fig. 2C), and SKi induced the appearance of higher-
molecular-mass forms (53 kDa and 100 to 130 kDa) (Fig. 2C). Treatment of cells with
MG132 also promotes the formation of a Degs1 ladder that is similar to that observed
in HEK293T cells (Fig. 2C). These ﬁndings indicate that, as in HEK293T cells, Degs1 is
subject to dynamic turnover via proteasomal degradation in PANC1 cells.
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FIG 1 Effect of ABC294640 or SKi on Degs1 protein laddering in HEK293T cells. Cells maintained in serum and grown to 70% conﬂuence were treated with
ABC294640 (ABC) (25 M) or SKi (10 M) for 24 h. In certain cases, cells were treated with scrambled (scr) or Degs1 siRNA (100 nM) for 48 h or with nutlin (Nut)
(10 M) or MG132 (10 M) for 30 min prior to treatment with SKi or ABC294640. Where indicated, cells were transfected with a HA-ubiquitin (Ub) plasmid
construct for 8 h prior to treatment with or without SKi. (A) Western blot probed with anti-Degs1 antibody showing the effect of SKi or ABC294640, in the
presence or absence of MG132, on Degs1 laddering. (B) Western blot probed with anti-Degs1 antibody showing the effect of Degs1 siRNA on the formation
of the Degs1 ladder in response to SKi. The bar graph demonstrates the reduction in polyubiquitinated Degs1 (Mr  46 kDa) expression levels by Degs1 siRNA
in the presence of SKi. Results are expressed as Degs1/GAPDH ratios (means  standard errors of the means [SEM] for 3 independent experiments; *, P  0.01
versus scrambled siRNA/SKi). (C) Western blot probed with anti-Degs1 antibody showing the localization of the Degs1 ladder in the pellet fraction. (D) Western
blot probed with anti-Degs1 antibody showing the presence of the Degs1 ladder in anti-Degs1 immunoprecipitates. (E) Western blot showing the formation
(Continued on next page)
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Therefore, we conclude that Degs1 is subject to polyubiquitination based on the
following: (i) SKi induced the formation of HA-ubiquitinated Degs1 forms, which was
detected in anti-Degs1 immunoprecipitates with anti-HA antibody on Western blots; (ii)
the formation of the Degs1 ladder is reduced by pretreating cells with the Mdm2
inhibitor nutlin; (iii) the proteasome inhibitors MG132 and bortezomib induce the
formation of the Degs1 ladder, consistent with the accumulation of polyubiquitinated
forms of Degs1 that are trapped due to inhibition of the proteasome; and (iv) the
formation of the Degs1 ladder is reduced by siRNA knockdown of Degs1.
Assessment of the roles of SK1 and SK2 in the polyubiquitination of Degs1. We
have previously shown that ABC294640 or SKi induces the proteasomal degradation of
SK1 in cancer cells (21, 23). This was also the case in HEK293T cells, where ABC294640
(25 M) or SKi (10 M) treatment reduced SK1 expression by 80%, which was
FIG 1 Legend (Continued)
of HA-ubiquitinated forms of Degs1 in response to SKi, detected in anti-Degs1 immunoprecipitates with anti-HA antibody (Ab). Also shown is a Western blot
of lysates from cells transfected with the vector or the HA-ubiquitin plasmid construct probed with anti-HA antibody. (F) Western blot probed with anti-Degs1
antibody showing the effect of nutlin on the formation of the Degs1 ladder in response to SKi. Blots in panels A, B, and F were reprobed for GAPDH using
anti-GAPDH antibody to ensure comparable protein loading. Results are representative of data from at least 3 independent experiments. Lanes C, control.
FIG 2 MG132- and bortezomib-induced formation of the Degs1 ladder. Cells maintained in serum and grown to
70% conﬂuence were treated with ABC294640 (25 M) or SKi (10 M) for 24 h. In certain cases, cells were treated
with scrambled siRNA or Degs1 siRNA (each at a ﬁnal concentration of 100 nM) for 48 h or with MG132 (10 M)
for 30 min prior to treatment with ABC294640 or SKi. Cells were also treated with bortezomib (5 or 10 nM) for 24
h. (A) Western blot probed with anti-Degs1 antibody showing the effect of Degs1 siRNA on Degs1 laddering
induced by MG132 in the presence or absence of SKi or ABC294640. (B) Western blot probed with anti-Degs1
antibody showing the effect of bortezomib (BTZ) on Degs1 laddering. (C) Western blot showing the formation of
the Degs1 ladder in response to SKi or MG132 in PANC1 cells. Blots were reprobed for GAPDH using anti-GAPDH
antibody to ensure comparable protein loading. Results are representative of data from at least 3 independent
experiments. Lanes C, control.
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reversed by MG132 (Fig. 3A). The Degs1 ladder was not induced by siRNA knockdown
of SK1 (Fig. 3B), which reduced SK1 protein expression by 70% (Fig. 3B). This suggests
that SK1 is not involved in promoting the formation of the Degs1 ladder in response to SKi.
This is supported by the fact that ABC294640 (25 M) induces the proteasomal degradation
of SK1 by 80% (Fig. 3A) in HEK293T cells yet fails to promote the formation of the Degs1
ladder at this concentration. Further conﬁrmation for the lack of a role for SK1 was obtained
using the SK1 inhibitor PF-543 (24), which exhibits a Ki of 4 nM for SK1 inhibition. In this
regard, PF-543 failed to induce formation of the Degs1 ladder (Fig. 3C).
Both ABC294640 and SKi also inhibit SK2 activity (25). Therefore, it is unlikely that
SK2 inhibition is involved in promoting the formation of the Degs1 ladder because
ABC294640 (25 M) failed to induce the Degs1 ladder (Fig. 1A). Moreover, siRNA
knockdown of SK2 failed to induce formation of the Degs1 ladder (Fig. 3D). The
efﬁciency of siRNA knockdown of the SK2 mRNA transcript was 50% (Fig. 3D). In
addition, neither SK1 nor SK2 knockdown affected the formation of the Degs1 ladder
in response to SKi (Fig. 3B and D).
Effects of SKi and ABC294640 on PARP cleavage and DNA synthesis. We next
tested the effects of SKi and ABC294640 on the growth and apoptosis of HEK293T cells.
For this purpose, we measured the cleavage of poly(ADP-ribose) polymerase (PARP)
and the induction of CCAAT enhancer binding protein homologous protein (CHOP)
expression as surrogate reporters for apoptosis (26), and we measured [3H]thymidine
incorporation into DNA to measure growth (although this does not exclude DNA
repair). Treatment of HEK293T cells with ABC294640 (25 M for 24 h) but not SKi (10
M for 24 h) induced PARP cleavage and CHOP expression and reduced DNA synthesis
(Fig. 4A to C), indicating that ABC294640 promotes apoptosis. The effect of ABC294640
on PARP cleavage and DNA synthesis was reversed by siRNA knockdown of Degs1
expression (Fig. 4A and C), indicating that Degs1 is involved in regulating apoptosis and
DNA synthesis in response to ABC294640. We also noted that a higher concentration of
ABC294640 (75 M for 24 h) produced a very weak Degs1 ladder (Fig. 4D), indicating
that ABC294640 is less potent in inducing posttranslational modiﬁcation of Degs1 than
SKi (Fig. 4A and C). We can therefore formally exclude the polyubiquitinated forms of
Degs1 from inducing apoptosis because SKi fails to promote this response.
Given the effects of ABC294640 on SK1 expression (Fig. 3A) and SK2 activity (25), it
was necessary to evaluate the roles of these lipid kinases in regulating apoptosis in
these cells. In this regard, SK1 knockdown with siRNA had no effect alone or on
ABC294640-induced PARP cleavage (Fig. 4E), while SK2 knockdown (50%) reduced
the cleavage of PARP in response to ABC294640 treatment (Fig. 4F). These ﬁndings
suggest that SK2 and native Degs1 might collaborate to induce apoptosis in HEK293T
cells in response to ABC294640.
Role of polyubiquitinated forms of Degs1 in regulating p38 MAPK and JNK
activation. To further explore whether the polyubiquitinated forms of Degs1 are protec-
tive against apoptosis, we assessed whether SKi might activate prosurvival signaling
pathways. In this regard, SKi induced an increase in the phosphorylation of p38 MAPK and
JNK in HEK293T cells (Fig. 5A). These are known as “alarm signals” that might function to
counter sustained UPR-induced cell death in this case. Indeed, treatment of cells with the
JNK inhibitor SP600125 induced the formation of cleaved PARP (Fig. 5B), while the p38
MAPK inhibitor SB203580 reduced DNA synthesis (Fig. 5C), suggesting that JNK is protective
against apoptosis, while p38 MAPK promotes DNA synthesis. In addition, while SKi alone
had no effect on DNA synthesis, it enhanced the inhibitory effect of SB203580 (Fig. 5C). This
might suggest that SKi is also capable of activating growth-inhibitory pathways but that
these are suppressed when phosphorylated p38 MAPK levels are increased by SKi. Further-
more, treatment of HEK293T cells with Degs1 siRNA abolished the effect of SKi on the p38
MAPK and JNK pathways (Fig. 5A). In order for p38 MAPK/JNK signaling in response to SKi
to be reduced by the siRNA knockdown of Degs1, the polyubiquitinated forms of Degs1 are
likely to have acquired a gain of function.
Alsanaﬁ et al. Molecular and Cellular Biology
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FIG 3 Assessment of the roles of SK1 and SK2 in the formation of the Degs1 ladder. Cells maintained in serum
and grown to 70% conﬂuence were treated with ABC294640 (25 M), SKi (10 M), or PF-543 (100 nM) for 24 h.
In certain cases, cells were treated with SK1 or SK2 siRNA (each at a ﬁnal concentration of 100 nM) for 48 h or
with MG132 (10 M) for 30 min prior to treatment with SKi or ABC294640. (A) Western blot probed with anti-SK1
antibody showing the effect of ABC294640 or SKi on SK1 expression and reversal by MG132. The bar graph
demonstrates the reduction in SK1 expression levels with SKi or ABC294640. Results are expressed as SK1/GAPDH
ratios (means  SEM for 6 independent experiments; *, P  0.01 versus the control). (B) Western blot probed with
anti-Degs1 antibody showing the lack of an effect of SK1 siRNA on the formation of the Degs1 ladder in response
to SKi. Also shown are a Western blot and a bar graph demonstrating the reduction in SK1 protein expression
with SK1 siRNA. Results are expressed as SK1/GAPDH ratios (means  SEM for 5 independent experiments; *,
P 0.01 versus scrambled siRNA). (C) Western blot probedwith anti-Degs1 antibody showing the lack of an effect
of PF-543 on the formation of the Degs1 ladder. (D) Western blot probed with anti-Degs1 antibody showing the
(Continued on next page)
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Degs1 siRNA reduces the expression of both native and polyubiquitinated forms of
Degs1 that accumulate in response to SKi (Fig. 2A). Therefore, the question arises as to
which form(s) of Degs1 (native or polyubiquitinated forms) accounts for the increases
in phosphorylated p38 MAPK and JNK levels. We can exclude native Degs1 because the
FIG 3 Legend (Continued)
lack of an effect of SK2 siRNA on the formation of the Degs1 ladder in response to SKi. Also shown are data from
RT-qPCR analysis demonstrating reductions in SK2 mRNA transcripts with SK2 siRNA. Results are expressed as
percent decreases in the expression of SK2 (means  SEM for 3 independent determinations; *, P  0.01 versus
scrambled siRNA). Blots were reprobed for GAPDH using anti-GAPDH antibody to ensure comparable protein
loading, and results are representative of data from at least 3 independent experiments. Lanes C, control.
FIG 4 Effect of ABC294640 or SKi on PARP cleavage in HEK293T cells. Cells maintained in serum and grown to 70% conﬂuence were
treated with ABC294640 (25 to 75 M) or SKi (10 M) for 24 h or the times indicated. In certain cases, cells were treated with
scrambled, Degs1, SK1, or SK2 siRNA (each at a ﬁnal concentration of 100 nM) for 48 h prior to treatment with ABC294640 or SKi. (A)
Western blot probed with anti-PARP antibody showing the effect of Degs1 siRNA, SKi, or ABC294640 (25 M) on PARP cleavage. (B)
Western blot probed with anti-CHOP antibody showing the effect of SKi (10 M), ABC294640 (25 M), or MG132 (MG) (10 M) on
CHOP expression. Also shown is the time-dependent increase in CHOP expression in response to ABC294640. (C) Bar graph showing
the effect of Degs1 siRNA, SKi, or ABC294640 (25 M) on DNA synthesis (*, P  0.05 for ABC294640/scrambled siRNA versus
control/scrambled siRNA; **, P  0.05 for ABC294640/scrambled siRNA versus ABC294640/Degs1 siRNA [n  3 independent
experiments]). (D) Western blot probed with anti-Degs1 antibody showing the effect of ABC294640 (25, 50, or 75 M) on Degs1
laddering. (E) Western blot probed with anti-PARP antibody showing the effect of SK1 siRNA, SKi, or ABC294640 (25 M) on PARP
cleavage. (F) Western blot probed with anti-PARP antibody showing the effect of SK2 siRNA, SKi, or ABC294640 (25 M) on PARP
cleavage. Blots were reprobed for GAPDH using anti-GAPDH antibody to ensure comparable protein loading. Results in panels A, B,
and D to F are representative of data from at least 3 independent experiments. Lanes C, control.
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levels of phosphorylated p38 MAPK and JNK are not signiﬁcantly reduced in cells
treated with Degs1 siRNA alone (Fig. 5A). To evaluate the role of SK1 or SK2 in
regulating p38 MAPK and JNK signaling, we used SK1 siRNA or SK2 siRNA. However,
neither siRNA recapitulated the effect of SKi on p38 MAPK and JNK phosphorylation
levels (Fig. 5D and E).
For completeness, we evaluated the effects of SB203580 (p38 MAPK inhibitor) and
SP600125 (JNK inhibitor) on the polyubiquitination of Degs1 in response to SKi.
FIG 5 p38 MAPK and JNK signaling. Cells maintained in serum and grown to 70% conﬂuence were treated with SKi (10 M) for 24 h. In
certain cases, cells were treated with scrambled, Degs1, SK1, or SK2 siRNA (each at a ﬁnal concentration of 100 nM) for 48 h or with
SB203580 (10 M) or SP600125 (20 M) for 30 min prior to treatment with and without SKi. (A) Western blot probed with anti-phospho-
p38 MAPK or anti-phospho-JNK antibodies showing the effect of Degs1 siRNA on the phosphorylation levels of p38 MAPK and JNK in
response to SKi. (B) Western blot probed with anti-PARP antibody showing the effect of SB203580 (SB) or SP600125 (SP) on PARP cleavage.
(C) Bar graph showing the effect of SKi with or without SB203580 on DNA synthesis (*, P  0.05 for SB203580 versus the control; **,
P  0.05 for SB203580/SKi versus SB203580 alone [n  3 independent experiments]). (D and E) Western blot probed with anti-phospho-
p38 MAPK and anti-phospho-JNK antibodies showing no effect of SK1 siRNA (D) or SK2 siRNA (E) on the phosphorylation levels of p38
MAPK and JNK. (F) Western blot probed with anti-Degs1 antibody showing the effect of SB203580 on Degs1 laddering in response to SKi.
Blots were reprobed for GAPDH using anti-GAPDH antibody, anti-p38 MAPK antibody, or anti-JNK antibody to ensure comparable protein
loading. Results in panels A, B, and D to F are representative of data from at least 3 independent experiments. Lanes C, control.
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Surprisingly, pretreatment of cells with SB203580 (Fig. 5F) but not SP600125 (data not
shown) decreased the formation of the Degs1 ladder in response to SKi. Thus, p38
MAPK might be involved in a positive-feedback loop that enhances the polyubiquiti-
nation of Degs1.
Effects of NAC, fenretinide, and GT11 on the polyubiquitination of Degs1.
Previous studies have proposed that SKi indirectly inhibits Degs1 activity via a mech-
anism involving an oxidative stress response and cytochrome b5 reductase (27). Simi-
larly, fenretinide has been shown to inhibit Degs1 activity and induce oxidative stress
(5, 28, 29). Therefore, we assessed whether the antioxidant N-acetyl-L-cysteine (NAC)
and fenretinide can affect the posttranslational modiﬁcation of Degs1. In this regard,
the pretreatment of HEK293T cells with NAC reduced the formation of the Degs1
ladder in response to SKi (Fig. 6A). Fenretinide also induced the formation of
posttranslationally modiﬁed forms of Degs1, and pretreatment with the antioxidant
NAC reduced their formation (Fig. 6B). To more directly establish a link between
compounds that can modulate Degs1 activity and formation of the Degs1 ladder,
we used the competitive Degs1 inhibitor GT11 {N-[(1R,2S)-2-hydroxy-1-hydroxymethyl-2-
(2-tridecyl-1-cyclopropenyl)ethyl]octanamide}. GT11 has been shown to competitively in-
hibit Degs1 with a Ki of 6 M (30), and treatment of primary neurons for 24 h maximally
inhibited the desaturation of ceramide at 100 nM (31). Higher concentrations of GT11 (10
FIG 6 Oxidative stress and polyubiquitination of Degs1. Cells maintained in serum and grown to 70% conﬂuence were treated with SKi
(10 M), MG132 (10 M), fenretinide (FEN) (1 M), or GT11 (10 nM to 10 M) for 24 h. In certain cases, cells were treated with NAC (10
mM) for 30 min prior to treatment with SKi, fenretinide, or GT11. (A and B) Western blot probed with anti-Degs1 antibody showing the
effect of NAC on Degs1 laddering in response to SKi (A) or fenretinide (B). (C) Western blot showing the lack of an effect of GT11 on Degs1
laddering. Blots were reprobed for GAPDH using anti-GAPDH antibody to ensure comparable protein loading. Results are representative
of data from at least 3 independent experiments. Lanes C, control.
Alsanaﬁ et al. Molecular and Cellular Biology
December 2018 Volume 38 Issue 23 e00222-18 mcb.asm.org 10
 o
n
 N
ovem
ber 14, 2018 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
M) inhibit S1P lyase activity (31). Therefore, we treated HEK293T cells with GT11 (10
nM to 10 M), which failed to induce the Degs1 ladder (Fig. 6C). Taken together, these
ﬁndings suggest that it might be necessary for SKi and fenretinide to induce oxidative
stress in order to indirectly stimulate the polyubiquitination of Degs1 and that the
effects are not likely a consequence of direct binding to Degs1.
Effects of ABC294640 and SKi on PERK and XBP-1s. Changes in the lipid com-
position of the ER membrane, and particularly ceramide/dihydroceramide, are involved
in ER stress. In addition, ER stress can contribute both prosurvival and apoptotic signals
to the cell. Therefore, we considered whether the regulation of Degs1 by SKi and
ABC294640 might involve this pathway. To evaluate this, we measured the levels of two
ER stress effectors, namely, protein kinase R-like ER kinase (PERK) and X-box binding
protein 1s (XBP-1s). Treatment of HEK293T cells with SKi induced a mobility shift in
PERK on SDS-PAGE gels (Fig. 7A), which has previously been reported to be a conse-
quence of phosphorylation (32). Tunicamycin (5 g/ml), a bona ﬁde inducer of ER
stress, also promoted a mobility shift in PERK (Fig. 7A).
The mobility shift in PERK induced by SKi was not reversed by siRNA knockdown of
Degs1 (Fig. 7B). Therefore, the SKi-induced phosphorylation of PERK likely does not
involve Degs1. Alternatively, inhibition of SK1 or SK2 activity by SKi might affect PERK
FIG 7 PERK signaling. Cells maintained in serum and grown to 70% conﬂuence were treated with ABC294640 (25
M) or SKi (10 M) for 24 h or with tunicamycin (5 g/ml) for up to 8 h. In certain cases, cells were treated with
scrambled, Degs1, SK1, or SK2 siRNA (each at a ﬁnal concentration of 100 nM) for 48 h prior to treatment with SKi.
Western blots probed with anti-PERK antibody show the effect of SKi, ABC294640, or tunicamycin (A), Degs1 siRNA
(B), SK1 siRNA (C), or SK2 siRNA (D) on the mobility shift of PERK induced by SKi. Blots were reprobed for GAPDH
or actin using anti-GAPDH or antiactin antibodies to ensure comparable protein loading. Results are representative
of data from at least 3 independent experiments. Lanes C, control.
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phosphorylation. However, neither SK1 nor SK2 knockdown with siRNA recapitulated or
modiﬁed the effects of SKi on PERK (Fig. 7C and D), thereby also possibly excluding
these kinases. This is consistent with the ﬁnding that ABC294640, which inhibits SK2
(25) and induces proteasomal degradation of SK1 in HEK293T cells (Fig. 3A), failed to
induce a mobility shift in PERK (Fig. 7A).
We next turned our attention to XBP-1s (Fig. 8). In this regard, neither ABC294640
nor SKi alone had any effect on XBP-1s expression. In contrast, MG132 induced a
modest increase in the expression of XBP-1s. However, this was markedly enhanced by
SKi (Fig. 8), which is signiﬁcant because the combination of SKi and MG132 strongly
stimulated the formation of the Degs1 ladder and particularly the accumulation of
posttranslationally modiﬁed Degs1 forms with a Mr of 50 kDa (Fig. 2A). Moreover, the
siRNA knockdown of Degs1 reduced the MG132/SKi-induced increase in XBP-1s ex-
pression (Fig. 8). In contrast, ABC294640 (25 M) reduced the MG132-induced increases
in XBP-1s levels (Fig. 8).
Effects of SKi and ABC294640 on sphingolipid levels. Since ABC294640 (25 M)
and SKi (10 M) have differential effects on Degs1, we investigated whether these are
reﬂected in changes in sphingolipids. First, we looked at dihydroceramide levels. In this
regard, both compounds induced only modest increases in dihydroceramide levels.
ABC294640 (25 M) induced increases in C16:0, C18:1, C22:0, C24:1, C24:0, and C26:1
dihydroceramide levels, with C20:0 dihydroceramide levels approaching signiﬁcance
(Fig. 9A). SKi also induced increases in dihydroceramide levels, although, in contrast to
ABC294640, only the levels of C16:0 and C24:0 dihydroceramides were elevated, while
the increase in the C24:1 dihydroceramide level approached statistical signiﬁcance (Fig.
9A). Hexosyl dihydroceramide levels were too low to produce a clear indication as to
whether they were changed (data not shown).
Both SKi and ABC294640 are SK1/SK2 inhibitors, and so we established their effects
on long-chain sphingoid bases. Treatment of the cells with SKi induced a reduction in
sphinganine 1-phosphate levels, with the decrease in S1P levels approaching statistical
signiﬁcance (P  0.06) (Fig. 9B), consistent with its inhibitory effect on SK1 and SK2
activity. This was accompanied by a lack of an effect on sphinganine levels but a
reduction in sphingosine levels. In contrast, ABC294640 induced an increase in sphin-
gosine, sphinganine, and S1P levels (Fig. 9B), which might reﬂect increased de novo
synthesis and/or uptake while reducing sphinganine 1-phosphate levels (Fig. 9B); the
latter effect is consistent with SK inhibition. In line with the elevation of sphingosine
and sphinganine levels, ABC294640 induced an increase in ceramide levels (Fig. 9C),
and this might also reﬂect an induction of de novo biosynthesis and/or uptake from the
medium. In this regard, ABC294640 induced an increase in the levels of various
ceramide molecular species (including C14:0, C16:0, C18:0, C18:1, C20:0, C22:0, C24:1, C24:0,
C26:0, and C26:1) (Fig. 9C), which is consistent with the ability of this compound to
induce apoptosis. In contrast, SKi induced a decrease in the levels of C18:0 and C20:0
ceramides, while it induced increased levels of C24:1 and C14:0 ceramides (Fig. 9C). SKi
had little effect on total ceramides, suggesting that it probably fails to raise the levels
of “apoptotic” ceramides, thereby accounting for its lack of an effect on PARP and CHOP
(Fig. 4A and B). In terms of sphingomyelin levels, ABC294640 induced an increase in the
levels of C20:0, C22:0, C24:0, C24:1, and C26:1 species, with the increase for C18:0 approach-
ing statistical signiﬁcance, while SKi had no effect (Fig. 10A). ABC294640 also increased
the levels of dihydrosphingomyelin (including C18:0, C22:0, C24:0, and C26:1, with C24:1
approaching statistical signiﬁcance [P  0.054]), while SKi increased the levels of C16:0
dihydrosphingomyelin (Fig. 10B).
DISCUSSION
The major ﬁnding of this study is that Degs1 is regulated by polyubiquitination.
Moreover, we demonstrate here that the native and polyubiquitinated forms of Degs1
exert opposing functions on cellular fate. Thus, the polyubiquitinated forms of Degs1
are linked with the activation of prosurvival and growth signaling pathways, e.g., JNK,
XBP-1s, and p38 MAPK (Fig. 11). The polyubiquitinated forms of Degs1 appear to be in
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transit to proteasomal degradation, as the accumulation of the forms is increased by
combined treatment of the cells with the proteasome inhibitor MG132 and SKi.
Therefore, it is possible that some compounds remove Degs1 from cells via the
ubiquitin-proteasomal degradation route, and this might account for cell death in-
duced by these compounds, which has been reported in the literature (7, 10–13).
However, the polyubiquitinated forms themselves are endowed with a prosurvival
function, and therefore, if the degradation rate is low, then these forms might pre-
dominate and thereby account for the cell survival function of Degs1 (5–7, 9, 14, 15).
We have also demonstrated a role for oxidative stress, p38 MAPK (functioning in a
positive-feedback mechanism of regulation), and Mdm2 in promoting the polyubiq-
uitination of Degs1. The mechanism by which p38 MAPK regulates the polyubiquiti-
nation of Degs1 remains to be determined. However, previous studies have shown that
tumor necrosis factor alpha (TNF-) uses the p38 MAPK pathway to stimulate the
expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle (33). There is
additional evidence for the link between p38 MAPK and Mdm2. Thus, hypoxia has been
shown to induce downregulation of Mdm2, and this can be reduced by p38 MAPK
inhibitors and by a dominant-interfering mutant of the p38-activating kinase mitogen-
activated protein kinase kinase 3 (34).
In contrast to the polyubiquitinated forms of Degs1, the native form of Degs1
appears to be linked with the induction of apoptosis (Fig. 11). In this regard, ABC294640
(25 M) fails to induce the polyubiquitination of Degs1 but promotes apoptosis. A
higher concentration of ABC294640 (75 M) stimulates the formation of the Degs1
ladder, suggesting that it is signiﬁcantly less potent than SKi.
We have also established the effects of SKi and ABC294640 on sphingolipid levels,
which provides information concerning the effect of modulating Degs1, SK1, and SK2
activity on the survival of HEK293T cells. Treatment of cells with SKi increased C16:0 and
C24:0 dihydroceramide levels. The increase in the levels of these species is relatively
modest and can be accounted for by the loss of some Degs1 via proteasomal degra-
dation. However, the selective effect on these particular dihydroceramide species is
somewhat surprising because this enzyme can catalyze the desaturation of many
different molecular species of dihydroceramide. The dihydroceramide proﬁle might, in
fact, be an average of some loss of Degs1 via proteasomal degradation and some gain
of function acquired by the polyubiquitinated forms. Second, the levels of C14:0 and
C24:1 ceramides were shown to be elevated in response to treatment of cells with SKi,
and it is tempting to speculate that these species might be formed from dihydrocera-
mide by the polyubiquitinated Degs1 forms. In this regard, these molecular species
might represent “prosurvival” ceramides linked to the activation of the p38 MAPK/JNK
and XBP-1s pathways. The gain of function acquired by the polyubiquitinated forms of
Degs1 might require redistribution to a speciﬁc functional compartment with effectors
of the survival pathways, where local regulation of discrete pools of speciﬁc dihydro-
FIG 8 Regulation of XBP-1s expression. Cells maintained in serum and grown to 70% conﬂuence were treated with ABC294640
(25 M) or SKi (10 M) for 24 h. In certain cases, cells were treated with scrambled or Degs1 siRNA (ﬁnal concentration of 100
nM) for 48 h or with MG132 (10 M) for 30 min prior to treatment with SKi or ABC294640. A Western blot probed with
anti-XBP-1s antibody shows the effect of Degs1 siRNA treatment on the induction of XBP-1s by MG132 in the presence and
absence of SKi or ABC294640. Blots were reprobed for GAPDH using anti-GAPDH antibody to ensure comparable protein
loading. Results are representative of data from at least 3 independent experiments. Lanes C, control.
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ceramide molecular species can take place. Indeed, Beauchamp et al. (35) reported that
Degs1 is N-myristoylated and targeted to the mitochondria, suggesting that there are
two pools of Degs1, one in the ER and one in the mitochondria. This requires further
investigation, as immunoﬂuorescence analysis with anti-Degs1 antibody did not reveal
any obvious change in the distribution of Degs1 with SKi (data not shown), although
the polyubiquitinated forms of Degs1 might be resident in the ER because of the link
with the activation of the ER stress-responsive effector JNK. The modest effect of SKi on
dihydroceramide levels might also suggest that the rates of proteasomal degradation
FIG 9 Effects of ABC294640 and SKi on dihydroceramide, sphingoid base, and ceramide levels. Cells maintained in serum
and grown to 70% conﬂuence were treated with ABC294640 (25 M) or SKi (10 M) for 24 h before snap-freezing. Lipid
extracts were analyzed by LC-MS for different molecular species of dihydroceramide (A), sphingoid bases (B), and
ceramides (C) (*, P  0.05 for ABC294640 or SKi versus the control for 3 independent samples). Sphinganine and
sphinganine 1-phosphate are denoted here dhSph and dhS1P, respectively. For panels A and C, the x axis annotates
different N-acyl chain lengths and double-bond molecular species.
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of Degs1 and, therefore, inactivation are rather low in HEK293T cells, thereby allowing
the intermediate polyubiquitinated forms to accumulate and to therefore instigate a
persistent cell survival program.
The treatment of HEK293T cells with ABC294640 increased both dihydroceramide
and ceramide levels. This suggests an overall increase in ﬂux through the de novo
ceramide pathway or increased cellular uptake. The increased levels of dihydrocera-
mide might effectively endow native Degs1 with a gain of function by a substrate
induction mechanism to promote the formation of ceramide species that promote
apoptosis. The changes in dihydroceramide levels with SKi and ABC294640 are consis-
tent with previous studies that reported that these compounds promote senescence of
androgen-independent LNCaP-AI prostate cancer cells associated with the proteasomal
degradation of SK1 and Degs1 (21) and increased p53 and p21 expression (21). The
inhibitory effects of SKi and ABC294640 on Degs1 activity result in increased dihydro-
ceramide levels in prostate cancer cells (23, 36). SKi has been proposed to also indirectly
inhibit Degs1 via a cytochrome b5 reductase-dependent mechanism (27) and also
increased dihydroceramide levels in ovarian cancer cells (37).
The treatment of cells with ABC294640 also increased both sphingosine and S1P
levels, which is rather surprising given its effect on inducing the proteasomal degra-
dation of SK1 in HEK293T cells and its characterization as an SK2 inhibitor. Nevertheless,
ABC294640 is a rather a weak inhibitor of SK2 (50% inhibitory concentration [IC50]  50
M) (38). Therefore, there might be sufﬁcient SK2 activity remaining in the presence of
ABC294640 to drive S1P formation as a consequence of elevated levels of sphingosine
that accumulates in response to ABC294640. ABC294640 also reduced sphinganine
1-phosphate levels, which is consistent with its ability to induce the proteasomal
degradation of SK1 in HEK293T cells. Therefore, these ﬁndings suggest that SK1 might
be more important than SK2 in catalyzing the formation of sphinganine 1-phosphate in
these cells. Indeed, a similar reduction in sphinganine 1-phosphate levels is observed
with SKi, which also induces the proteasomal degradation of SK1. SKi also reduces S1P
FIG 10 Effects of ABC294640 and SKi on sphingomyelin and dihydrosphingomyelin levels. Cells maintained in serum and
grown to 70% conﬂuence were treated with ABC294640 (25 M) or SKi (10 M) for 24 h before snap-freezing. Lipid extracts
were analyzed by LC-MS for different molecular species of sphingomyelin (SM) (A) and dihydrosphingomyelin (B) (*, P  0.05
for ABC294630 or SKi versus the control for 3 independent samples). The x axis annotates different N-acyl chain lengths and
double-bond molecular species.
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levels albeit moderately. A possible explanation for the difference in the actions of
ABC294640 and SKi on S1P levels, then, is that SKi is a much stronger inhibitor of SK2
activity (IC50  2 M) (our unpublished data) than ABC294640, and therefore, S1P levels
might be predominantly regulated by SK2 in HEK293T cells.
The ﬁndings presented in this paper reveal that Degs1 is a very versatile enzyme,
and polyubiquitination might convert the enzyme from being proapoptotic to being
prosurvival. This might account for various conﬂicting reports on the role of Degs1 in
promoting apoptosis or cell survival mediated by, for instance, autophagy (for a review,
see reference 4). There is evidence for similar regulation of CerS1 by the ubiquitin-
proteasome degradation pathway. For instance, stress induces the translocation of
CerS1 from the ER to the Golgi apparatus and promotes its proteasomal degradation in
HEK293 cells (39). Moreover, overexpression of CerS1 increases the activation of p38
MAPK by cisplatin in HEK293 cells (40). These ﬁndings are intriguing and suggest that
CerS1 and Degs1 might operate through a similar linked ubiquitin-proteasomal deg-
radation mechanism in response to chemical stress that results in the activation of the
p38 MAPK pathway.
The prosurvival function of Degs1 is likely to be dictated by the lifetime of the
polyubiquitinated forms of Degs1 in various different cellular systems. These ﬁndings
might have important consequences when evaluating Degs1 as a target for therapeutic
treatment of cancer. Our ﬁndings reveal possible modes of action by which drugs
targeting Degs1 might act. First, drugs that prevent polyubiquitination of Degs1 might
promote cell death if they also increase de novo biosynthesis of apoptotic ceramide.
Second, drugs that accelerate the proteasomal degradation of Degs1 might remove the
prosurvival function of the polyubiquitinated forms to potentially kill cancer cells via
apoptotic/senescent pathways.
MATERIALS AND METHODS
Materials. All general biochemicals were from Sigma (Poole, UK). ABC294640 (catalogue number
S7174) was obtained from Stratech Scientiﬁc (UK). SKi (catalogue number 567731) was obtained from
Merck Biosciences (Nottingham, UK). MG132 (catalogue number C2211), N-acetyl-L-cysteine (catalogue
number A7250), nutlin (catalogue number N6287), and protein A-Sepharose 4B Fast Flow (catalogue
number P9424) were obtained from Sigma (Poole, UK). SP600125 (catalogue number BML-EI305) and
SB203580 (catalogue number BML-EI286) were obtained from Enzo Life Sciences (UK). Bortezomib
(catalogue number sc-217785) and fenretinide (catalogue number HY-15373) were obtained from Insight
Biotechnology Ltd. (UK). Anti-glyceraldehyde-3-phosphate dehydrogenase (anti-GAPDH) (catalogue
number sc-47724) antibody was obtained from Insight Biotechnology Ltd. (UK); anti-Degs1 (catalogue
number ab185237) antibody was obtained from Abcam; and anti-phospho-JNK (catalogue number
4671), anti-phospho-p38 MAPK (catalogue number 9211), anti-PARP (catalogue number 9542), anti-PERK
(catalogue number 5683), anti-CHOP (catalogue number 5554), and anti-XBP-1s (catalogue number
12782) antibodies were obtained from New England BioLabs Ltd. (Hitchin, UK). Anti-SK1 antibody was
FIG 11 Schematic showing the different roles of native and polyubiquitinated Degs1 forms in regulating
prosurvival/growth and apoptotic pathways in HEK293T cells. Native Degs1 is proposed to regulate the
formation of apoptotic ceramide species, while polyubiquitinated Degs1 forms are proposed to regulate
the formation of prosurvival/growth ceramide species. ROS, reactive oxygen species.
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custom-made by Abcam. DharmaFECT reagent; ON-TARGETplus SMARTpool; and Degs1, SK1, and SK2
siRNAs were obtained from Dharmacon (Cromlington, UK). Scrambled siRNA (Allstars negative control)
was obtained from Qiagen (Crawley, UK). [methyl-3H]thymidine (25 Ci/mmol; 37 MBq/ml) (catalogue
number NET027A) was obtained from PerkinElmer (UK). The internal standard mix for quantitation of the
sphingolipids by liquid chromatography (LC)-tandem mass spectrometry (MS) (catalogue number LM-
6002) was obtained from Avanti Polar Lipids (Alabaster, AL). GT11 was obtained from Avanti Polar Lipids.
Cell culture. HEK293T and PANC1 cells were maintained in Dulbecco’s modiﬁed Eagle’s medium
(DMEM)-GlutaMAX supplemented with 100 U/ml penicillin, 100 g/ml streptomycin, and 10% (vol/vol)
fetal bovine serum at 37°C with 5% CO2 before treatment with compounds.
[3H]thymidine incorporation. HEK293T cells (approximately 70% conﬂuent) in 24-well plates were
incubated with compounds or the vehicle (dimethyl sulfoxide [DMSO]; 0.1% [vol/vol] ﬁnal concentration),
as detailed in the ﬁgure legends, for 20 h prior to the addition of [3H]thymidine (9.25 kBq per well) for
a further 5 h. Incubations were terminated by removing the medium and immediately adding 1 ml of
ice-cold 10% (wt/vol) trichloroacetic acid, and the mixture was placed on ice for 10 min. This was
replaced with a further 1 ml of ice-cold 10% (wt/vol) trichloroacetic acid for 10 min, and this step was
repeated once more. Residual nuclear material was dissolved in 0.25 ml of 0.1% SDS–0.3 M NaOH.
[3H]thymidine uptake was quantiﬁed by liquid scintillation counting. Radiometric values (means 
standard deviations [SD]) were obtained from 3 or more independent experiments.
siRNA transfection. HEK293T cells were transiently transfected with siRNA constructs or scrambled
siRNA (as a negative control) at a ﬁnal concentration of 100 nM. Cells were transfected at approximately
50 to 60% conﬂuence and maintained in the transfection mixture for 48 h.
Immunoprecipitation. Cells were placed in ice-cold lysis buffer (500 l/3 wells) containing 137 mM
NaCl, 2.7 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 1% (wt/vol) Na deoxycholate, 10% (vol/vol) glycerol, 20 mM
Tris base, 1 mg/ml bovine serum albumin (BSA), 0.5 mM Na3VO4, 0.2 mM phenylmethylsulfonyl ﬂuoride
(PMSF), and leupeptin and aprotinin (both at 10 g/ml) (pH 8.0). The samples were homogenized using
a 0.24-mm-gauge needle and syringe and left to shake at 4°C for 60 min. After centrifugation to remove
cell debris, 250 l of the supernatant was precleared with 20 l of protein A-Sepharose beads (1:1 with
lysis buffer for 20 min at 4°C) before subsequent immunoprecipitation by adding 2 l of the anti-Degs1
antibody and 20 l protein A-Sepharose beads (1:1 with lysis buffer for 2 h at 4°C). Immunoprecipitates
were collected by centrifugation and washed three times with buffer A (10 mM HEPES, 100 mM NaCl,
0.5% [vol/vol] NP-40, and 0.2 mM PMSF [pH 7.0]) and three times with buffer B (buffer A without NP-40).
The beads were then sedimented by centrifugation, the supernatant was removed, and 20 l of Laemmli
buffer (0.125 M Tris-HCl, 10% [vol/vol] 2-mercaptoethanol, 20% [vol/vol] glycerol, 4% [wt/vol] SDS, and
0.004% [wt/vol] bromophenol blue [pH 6.7]) was added to the beads, which were then heated at 100°C
for 3 min. The samples were then subjected to SDS-PAGE.
Western blotting. Upon treatment, HEK293T cells were lysed in sample buffer containing 62.5 mM
Tris-HCl (pH 6.7), 0.5 M sodium pyrophosphate, 1.25 mM EDTA, 1.25% (wt/vol) sodium dodecyl sulfate,
0.06% (wt/vol) bromophenol blue, 12.5% (vol/vol) glycerol, and 50 mM dithiothreitol. Proteins were
separated on a 10% (vol/vol) acrylamide-bisacrylamide gel and transferred to a nitrocellulose Hybond
membrane (GE Healthcare). Membranes were blocked in 5% (wt/vol) BSA (Fisher) in TBST buffer
containing 20 mM Tris-HCl (pH 7.5), 48 mM NaCl, and 0.1% (vol/vol) Tween 20 for 1 h at room
temperature prior to incubation with primary antibody (diluted in blocking buffer) overnight at 4°C.
Following three washes in TBST, membranes were incubated with horseradish peroxidase-conjugated
anti-mouse or anti-rabbit IgG secondary antibody, as required, for 1 h at room temperature. Immuno-
reactive protein bands were visualized using enhanced chemiluminescence.
RNA extraction. Total RNAs from the cell samples were isolated using an RNeasy Plus minikit
(Qiagen, Manchester, UK) according to the manufacturer’s instructions. Spectrophotometric analysis with
a Nanodrop 2000C instrument (ThermoFisher Scientiﬁc, Renfrew, UK) was performed to obtain the RNA
concentrations, and all of the RNAs had A260/A280 ratios of approximately 2.1. The RNAs were stored at
80°C until required.
Gene expression analysis by quantitative real-time PCR. RNAs from each cell sample were reverse
transcribed to cDNA with a Tetro cDNA synthesis kit (Bioline, London, UK), along with aliquots processed
without reverse transcriptase to function as no-template controls for real-time quantitative PCR (RT-
qPCR), and were stored at 20°C. RT-qPCR was conducted by using PrimeTime qPCR probe assays for
SPHK2 (assay Hs.PT.58.3726704) and GAPDH (assay Hs.PT.39a.22214836) as the reference gene with
PrimeTime gene expression master mix (Integrated DNA Technologies, Leuven, Belgium). Thermal
cycling was carried out on an ABI StepOnePlus real-time PCR system (Applied Biosystems, Warrington,
UK) under the following protocol: polymerase activation at 95°C for 3 min followed by 40 cycles of
denaturation at 95°C for 5 s and annealing/extension at 60°C for 30 s. Relative quantiﬁcation of gene
expression between the samples treated with the control scrambled siRNA and those treated with SPHK2
siRNA was performed by using the 2ΔΔCT method to determine the percent knockdown of SPHK2
expression (41).
Lipidomics. HEK293T cells were treated with the vehicle (DMSO; 0.1% [vol/vol] ﬁnal concentration),
ABC294640 (25 M), or SKi (10 M) for 24 h and then carefully rinsed twice with 1 ml ice-cold
phosphate-buffered saline (PBS) before being scraped into ice-cold PBS. Cells were pelleted by centrif-
ugation (180  g at 4°C for 3 min), and the supernatant was carefully removed. The cell pellet was
snap-frozen in liquid nitrogen for 5 s before being stored at 80°C for sphingolipid analysis, which was
conducted as described previously (42, 43), using liquid chromatography, electrospray ionization-tandem
mass spectrometry, and multiple-reaction monitoring for quantitation.
Densitometry. Quantiﬁcation of immunoreactive bands was performed using ImageJ.
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